The Ultrasound-Guided Breast Biopsy Market is estimated to be valued at USD 907.0 million in 2025 and is projected to reach USD 1958.1 million by 2035, registering a compound annual growth rate (CAGR) of 8.0% over the forecast period.
The ultrasound-guided breast biopsy market has been expanding steadily due to the growing emphasis on early detection of breast abnormalities and the increasing adoption of minimally invasive diagnostic procedures. Continuous advancements in ultrasound imaging technologies have improved the precision and efficiency of breast biopsies, reducing patient discomfort and procedure time.
Medical practitioners have preferred ultrasound guidance for its real-time visualization and ability to target suspicious lesions with greater accuracy. Rising breast cancer screening rates and heightened awareness of preventive healthcare have also contributed to an increase in biopsy procedures worldwide.
Healthcare systems have been actively investing in diagnostic imaging equipment and expanding breast care units to address the growing patient population. Looking ahead, market growth is expected to be supported by technological improvements in biopsy needles and the integration of artificial intelligence in ultrasound platforms. Segmental leadership is anticipated to remain with Core needle (CN) ultrasound-guided breast biopsy as the leading procedure and Hospitals as the primary end user for these diagnostic services.
The market is segmented by Procedure and End User and region. By Procedure, the market is divided into Core needle (CN) ultrasound-guided breast biopsy, Fine needle aspiration (FNA) ultrasound-guided breast biopsy, Vacuum-assisted device (VAD) ultrasound-guided breast biopsy, and Wire localization ultrasound-guided breast biopsy. In terms of End User, the market is classified into Hospitals, Clinics, Diagnostics Laboratories, and Others. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The market is segmented by Procedure and End User and region. By Procedure, the market is divided into Core needle (CN) ultrasound-guided breast biopsy, Fine needle aspiration (FNA) ultrasound-guided breast biopsy, Vacuum-assisted device (VAD) ultrasound-guided breast biopsy, and Wire localization ultrasound-guided breast biopsy. In terms of End User, the market is classified into Hospitals, Clinics, Diagnostics Laboratories, and Others. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The Core needle (CN) ultrasound-guided breast biopsy segment is projected to hold 49.6% of the market revenue in 2025, sustaining its position as the most preferred procedure type. This segment’s growth has been supported by the clinical effectiveness of core needle biopsy in obtaining adequate tissue samples for accurate pathological assessment.
Clinicians have relied on this procedure for its balance of diagnostic precision and minimal invasiveness, making it suitable for both benign and malignant lesion evaluations. Compared to other biopsy methods, core needle biopsy has provided quicker recovery times and reduced the need for surgical intervention.
The procedure has gained acceptance in outpatient and day-care settings due to its safety profile and cost-efficiency. With increasing screening initiatives and patient awareness driving early detection efforts, the Core needle (CN) ultrasound-guided breast biopsy segment is expected to remain at the forefront of breast biopsy procedures.
The Hospitals segment is projected to account for 52.3% of the ultrasound-guided breast biopsy market revenue in 2025, establishing itself as the largest end user. Growth in this segment has been driven by the comprehensive diagnostic and therapeutic services offered by hospitals, which have made them the preferred choice for breast health evaluations.
Hospitals have been equipped with advanced ultrasound imaging systems and multidisciplinary breast care teams, enabling them to provide accurate biopsy services and timely treatment planning. Patients have consistently sought hospital-based diagnostics due to the availability of specialized radiologists and pathologists, ensuring reliable results.
Additionally, healthcare policies in many regions have prioritized hospital settings for early breast cancer detection programs and screening initiatives. As the prevalence of breast cancer continues to rise, hospitals are expected to maintain their leadership in biopsy procedure volume, supported by their integrated care approach and expanding diagnostic capabilities.
Ultrasound-guided breast biopsy is comparatively less invasive than other surgical biopsies, it leaves little scarring and can be performed in a limited time frame. These factors, combined together, will increase the adoption rate of ultrasound-guided breast biopsy.
In addition to this, ultrasound-guided breast biopsy does not carry ionizing radiation and provides faster results. It is also less expensive and has shorter recovery period. On the back of these factors, demand in the market is projected to increase at a considerable pace over the forecast period.
Ultrasound-guided breast biopsy also has certain aspects that impede sales in the market. The ultrasound-guided breast biopsy is known to carry a risk of bleeding that forms hematoma because of which consumers might reject this method of biopsy. This in turn hampers the growth in the ultrasound-guided breast biopsy market.
Furthermore, other factors such as discomfort experienced by patients during biopsy and the cost of an ultrasound machine might also impede the growth in ultrasound-guided breast biopsy market over the forecast period.
The American Cancer Society’s estimates for the year 2025 states that there will be 287,850 new cases of breast cancer, with 43,250 deaths. This rising prevalence of breast cancer along with an increasingly alert population may increase the demand for ultrasound-guided breast biopsy in North America.
Thus, ultrasound-guided breast biopsy market in North America is expected to exhibit a significant growth rate for the forecast period. Advancing technologies, high investments in the healthcare sector, and increasing production of new and improved imaging technologies will augment sales in the ultrasound-guided breast biopsy market in North America.
ncreasing awareness regarding early diagnosis and treatment of breast cancer among individuals across Asia Pacific is expected to create opportunities for growth in the market. Owing to rising amount of campaigns about breast cancer, majority of the population is aware about diagnosis and treatment methods for breast cancer. This is expected to boost the Asia Pacific ultrasound-guided breast biopsy market over the forecast period.
Leading players operating in the global ultrasound-guided breast biopsy market include Hologic, Inc., Medsurge Ind Private Limited among others.
Key companies in the market are engaged in developing their portfolio of breast biopsy products and accessories. The focus is also on contracts and partnerships to launch insight driven products, product commercialization and pipeline development in order to strengthen market position.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8% from 2025 to 2035 |
| Base Year for Estimation | 2024 |
| Historical Data | 2020 to 2024 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in million and CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
Procedure, End User, Region |
| Countries Covered | North America (USA, Canada), Latin America (Mexico, Brazil), Western Europe (Germany, Italy, France, UK, Spain, Nordic countries, Belgium, Netherlands, Luxembourg), Eastern Europe (Russia, Poland), Asia-Pacific Excluding Japan(China, India, ASEAN, Australia & New Zealand), Japan, Middle East and Africa (GCC Countries, South Africa, North Africa)
|
| Key Companies Profiled | Hologic Inc; Medsurge Ind Private Limited |
| Customization | Available Upon Request |
The global ultrasound-guided breast biopsy market is estimated to be valued at USD 907.0 million in 2025.
It is projected to reach USD 1,958.1 million by 2035.
The market is expected to grow at a 8.0% CAGR between 2025 and 2035.
The key product types are core needle (cn) ultrasound-guided breast biopsy, fine needle aspiration (fna) ultrasound-guided breast biopsy, vacuum-assisted device (vad) ultrasound-guided breast biopsy and wire localization ultrasound-guided breast biopsy.
hospitals segment is expected to dominate with a 52.3% industry share in 2025.
Explore Similar Insights
Ultrasound-Guided Breast Biopsy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
